EP1762233B1 - Agent préventif des lésions induites par l'oxygène pendant la plongée sous-marine - Google Patents

Agent préventif des lésions induites par l'oxygène pendant la plongée sous-marine Download PDF

Info

Publication number
EP1762233B1
EP1762233B1 EP06090157A EP06090157A EP1762233B1 EP 1762233 B1 EP1762233 B1 EP 1762233B1 EP 06090157 A EP06090157 A EP 06090157A EP 06090157 A EP06090157 A EP 06090157A EP 1762233 B1 EP1762233 B1 EP 1762233B1
Authority
EP
European Patent Office
Prior art keywords
vitamin
oxygen
diving
divers
fort
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP06090157A
Other languages
German (de)
English (en)
Other versions
EP1762233A1 (fr
Inventor
Felix Schielein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1762233A1 publication Critical patent/EP1762233A1/fr
Application granted granted Critical
Publication of EP1762233B1 publication Critical patent/EP1762233B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • the invention relates to medicaments by which divers in chronic doses by exposure to elevated oxygen partial pressures during dives are avoided.
  • Increased oxidative stress primarily damages ground tissue, in particular proteoglycan structures are attacked which are of central importance for the smooth functioning of many biological processes (immune system, detoxification, electrical tonus, information transport, water balance, etc.). It is important to protect these basic tissue structures in order to avoid the chronic effects of oxygen oversupply.
  • the ambient pressure increases very quickly when diving.
  • the pressure of the breathing gas increases rapidly with increasing water depth. For every 10 m of immersion, the pressure increases by 1 bar. It follows that a diver at a depth of 10 m is already exposed to a pressure of 2 bar, to a pressure of 3 bar at a depth of 20 m and to a pressure of 4 bar at a depth of 30 m.
  • the oxygen partial pressure in body tissues increases considerably, d. H.
  • a diver takes disproportionate amounts of oxygen under unphysiologically high pressure conditions.
  • the increased oxygen supply results in an excessive radical load.
  • the cells are unable to trap this increased radical load alone.
  • the diver is not immediately aware of the resulting chronic damage to the proteoglycan structures of the interstitium. Obvious illnesses, such as As the destruction of the articular cartilage substance, the diver often feels years later.
  • nitrox gases oxygen-rich and nitrogen-poor breathing gases.
  • nitrogen nitrogen
  • oxygen oxygen
  • Nitrox does not refer to a gas mixture with a fixed percentage of gas, but only gives information about its main constituents. In this context is also spoken of "technical diving". It is possible to measure the radical load of the tissue. Thus, free radicals can be detected under physiological conditions with the so-called FORT test.
  • the FORT test detects hydroperoxides (ROOH) as a valid free radical index.
  • the measurement results range from 200 FORT units, which are considered normal physiological values, to over 500 FORT units.
  • the drug described below represents the most advantageous composition for the solution of the problem underlying the prevention of increased radical concentrations in the tissue after dives.
  • a medicament of the following composition before the dive Vitamin B1 1 to 10 mg, Vitamin B2 1 to 10 mg, nicotinamide 10 to 100 mg, Vitamin B6 1 to 10 mg, vitamin C 0.5 to 5 g, Vitamin E 100 to 1000 iE, zinc 50 to 200 mg, selenium 50 to 200 ⁇ g, magnesium 100 to 500 mg, L-cystine 50 to 200 mg, Coenzyme Q10 5 to 40 mg
  • a drug of the following composition Vitamin B1 3 to 7 mg, Vitamin B2 3 to 7 mg, nicotinamide 30 to 70 mg, Vitamin B6 3 to 7 mg, vitamin C 1.5 to 3 g, Vitamin E 400 to 600 iE, zinc 50 to 200 mg, selenium 80 to 150 ⁇ g, magnesium 100 to 500 mg, L-cystine 80 to 150 mg, Coenzyme Q10 10 to 25 mg
  • the medicines mentioned in the following examples were prepared and given to volunteers for oral administration.
  • the radical concentration in the tissue was determined after several deep dives by FORT-test and compared with the corresponding values of non-treated subjects who had also experienced the same pressure regime.
  • Example 1 Drugs for the prevention of oxidative stress damage during diving
  • Example 2 Medicaments for the prevention of damage by oxidative stress during diving

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)

Claims (2)

  1. Médicament pour la prévention de dommages provoqués par un stress oxydant lors de la plongée, contenant, par unité d'administration de la vitamine B1 1 à 10 mg, de la vitamine B2 1 à 10 mg, du nicotinamide 10 à 100 mg, de la vitamine B6 1 à 10 mg, de la vitamine C 0,5 à 5 g, de la vitamine E 100 à 1000 i.E., du zinc 50 à 200 mg, du sélénium 50 à 200 µg, du magnésium 100 à 500 mg, de la L-cystine 50 à 200 mg et de la coenzyme Q10 5 à 40 mg.
  2. Médicament selon 1a revendication 1, les quantités par unité d'administration étant : vitamine B1 3 à 7 mg, vitamine B2 3 à 7 mg, nicotinamide 30 à 70 mg, vitamine B6 3 à 7 mg, vitamine C 1,5 à 3 g, vitamine E 400 à 600 i.E., zinc 50 à 200 mg, sélénium 80 à 150 µg, magnésium 100 à 500 mg, L-cystine 80 à 150 mg et coenzyme Q10 10 à 25 mg.
EP06090157A 2005-09-08 2006-09-08 Agent préventif des lésions induites par l'oxygène pendant la plongée sous-marine Not-in-force EP1762233B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005043403 2005-09-08

Publications (2)

Publication Number Publication Date
EP1762233A1 EP1762233A1 (fr) 2007-03-14
EP1762233B1 true EP1762233B1 (fr) 2008-03-26

Family

ID=37603385

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06090157A Not-in-force EP1762233B1 (fr) 2005-09-08 2006-09-08 Agent préventif des lésions induites par l'oxygène pendant la plongée sous-marine

Country Status (3)

Country Link
EP (1) EP1762233B1 (fr)
AT (1) ATE390131T1 (fr)
DE (1) DE502006000524D1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100522A1 (fr) * 2008-03-12 2009-09-16 Universite Joseph Fourier Nouveaux composites à base de sélénium, leur utilisateur et processus de préparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20116346U1 (de) * 2001-10-05 2001-12-20 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt u.a. mit Vitaminen und Carotinoiden

Also Published As

Publication number Publication date
DE502006000524D1 (de) 2008-05-08
ATE390131T1 (de) 2008-04-15
EP1762233A1 (fr) 2007-03-14

Similar Documents

Publication Publication Date Title
Long et al. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model
Bryan et al. Oxygen toxicity
EP1782824B1 (fr) Compositions pharmaceutiques sous forme d'hydrogel contenant de la diamino-oxydase
EP1957037B1 (fr) Composition pharmaceutique de fentanyl pour administration nasale
Ahmad et al. Analysis of antioxidant activity and total phenolic content of some homoeopathic mother tinctures
EP2594283A1 (fr) Préparation aérosol à base d'aprotinine pour traiter les infections respiratoires virales
EP3439742B1 (fr) Compositions cosmétiques protégeant contre les polluants atmosphériques
EP1762233B1 (fr) Agent préventif des lésions induites par l'oxygène pendant la plongée sous-marine
DE10303229B4 (de) Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
DE10330768A1 (de) Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
DE60000325T2 (de) Therapeutische Verwendung eines Helium/Oxygen Gemisches, insbesondere für die Behandlung von Asthma
Stone et al. The role of antioxidant nutrients in preventing hyperbaric oxygen damage to the retina
KR101826211B1 (ko) 항산화 및 미세먼지 축적 억제 기능을 갖는 수소수의 제조 장치 및 방법과 이를 이용하여 제조된 수소수
EP2090296A2 (fr) Utilisation de complexes de matière active à base de panthénol, glycérine, citrate et/ou bisabolol contre les allergies au pollen
US6660761B2 (en) Method of treatment for fungal infections with a synergistic formulation of antifungal agents
US20170095505A1 (en) Combination of xenon and an antioxidant to control a parkinson's disease-type neurodegenerative disease
DE102018007480A1 (de) Arznei- oder Nahrungsergänzungsmittel zur Aufrechterhaltung der Gesundheit von Gehirnzellen und/oder der Behandlung von geschädigten Gehirnzellen durch Aktivierung des Zellstoffwechsels der Gehirnzellen und/oder zum präventiven Schutz durch Erhöhung der Antioxidantien Konzentration im Gehirn.
Alansari Impact of Code Red energy drink on the functions and structure of the kidney of Wistar Albino rats: possible therapeutic effects of blueberry ethanolic extract
DE4316293A1 (de) Verwendung einer Kombination von Anserin/Carnosin und Hypotaurin/Taurin zur Bekämpfung entzündlicher Erkrankungen
DE102019129085A1 (de) Präparat zur Regeneration und Befeuchtung der Nasenschleimhaut
Maduka et al. Effect of Coconut Water on Lipid Peroxidation and Some Antioxidant Status of Diabetic Rats
RU2757220C1 (ru) Фармацевтическая композиция для профилактики и лечения синдрома поликистозных яичников
DE69902091T2 (de) Ionische wässerige zusammensetzung enthaltend levomenthol
DE60221903T2 (de) Verwendung synergistischer formulierungen von antifungusmitteln für die behandlung von pilzinfektionen
CN116870028B (zh) 一种抑菌口腔喷雾及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17P Request for examination filed

Effective date: 20070717

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/375 20060101ALI20070925BHEP

Ipc: A61K 33/30 20060101ALI20070925BHEP

Ipc: A61K 31/355 20060101ALI20070925BHEP

Ipc: A61K 31/4415 20060101ALI20070925BHEP

Ipc: A61K 31/455 20060101ALI20070925BHEP

Ipc: A61K 31/122 20060101ALI20070925BHEP

Ipc: A61K 31/51 20060101ALI20070925BHEP

Ipc: A61K 33/04 20060101ALI20070925BHEP

Ipc: A61K 31/525 20060101ALI20070925BHEP

Ipc: A61K 33/06 20060101ALI20070925BHEP

Ipc: A61K 31/195 20060101ALI20070925BHEP

Ipc: A61K 31/00 20060101AFI20070925BHEP

Ipc: A61P 39/06 20060101ALI20070925BHEP

RTI1 Title (correction)

Free format text: PREVENTIVE AGENT FOR OXYGEN-INDUCED DAMAGES FROM DIVING

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 502006000524

Country of ref document: DE

Date of ref document: 20080508

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080707

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080901

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080726

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20081230

BERE Be: lapsed

Owner name: SCHIELEIN, FELIX

Effective date: 20080930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080626

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080930

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20090921

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080908

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080627

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100923

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100924

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100908

Year of fee payment: 5

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110908

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502006000524

Country of ref document: DE

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110908

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 390131

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110908